Located in Budapest, AMRI Hungary has become the European center for AMRI, a global pharmaceutical research, development and manufacturing company with a full range of integrated services-from the identification of hit compounds, to powerful medicinal chemistry SAR optimization, to the production of pharmaceutical ingredients for clinical and commercial use.

Through the acquisition, clients of AMRI Hungary now have access to the comprehensive services provided by AMRI. Moreover, the integration of AMRI's research sites in the United States, Europe, and Asia provides the company's customers with a flexible range of services, capabilities and cost structures. As part of the AMRI brand, AMRI Hungary integrates innovative, early stage drug discovery technologies, including proprietary methods in the area of library synthesis, compound collections and lead discovery. In the future, AMRI Hungary plans to expand its capabilities in medicinal chemistry and SAR development.

The first tangible advantage of AMRI Hungary's addition to the global AMRI network is the availability of AMRI Hungary's new, expanded and integrated lead-seeking library-which is more diverse than before and includes new core structures.

Albany Molecular Research, Inc. is a global drug discovery company that provides chemistry services to pharmaceutical and biotechnology companies and conducts its own proprietary R&D programs. For more information, visit www.albmolecular.com.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words and include, without limitation, statements regarding the company's proposed expansion in Budapest. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission on March 16, 2006 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.